Laninamivir

Laninamivir

Clinical data
Routes of administration	Inhalation
ATC code	J05AH04 ( WHO )
Identifiers
IUPAC name (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-[(1R,2R)-3-hydroxy-2-methoxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
CAS Number	203120-17-6  N
PubChem CID	502272
ChemSpider	439182  Y
UNII	B408IW3GL5
ChEMBL	ChEMBL466246  Y
CompTox Dashboard (EPA)	DTXSID60942457
Chemical and physical data
Formula	C13H22N4O7
Molar mass	346.340 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O)C=1O[C@@H]([C@H](OC)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](/N=C(\N)N)C=1
InChI InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1 Y Key:QNRRHYPPQFELSF-CNYIRLTGSA-N Y
NY  (what is this?)    (verify)

Inavir

Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. ^[1] It is currently in Phase III clinical trials. ^[2] It is a long-acting neuraminidase inhibitor administered by inhalation. ^[3]

Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals ^[4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. ^[5] It is under clinical evaluations in other countries. ^{[3] [6]}

References

1. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (January 2009). "CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity". Antimicrobial Agents and Chemotherapy. 53 (1): 186–192. doi:10.1128/AAC.00333-08. PMC   2612152 . PMID   18955520.
2. Hayden F (January 2009). "Developing new antiviral agents for influenza treatment: what does the future hold?". Clinical Infectious Diseases. 48. 48 Suppl 1 (S1): S3-13. doi: 10.1086/591851 . PMID   19067613.
3. Samson M, Pizzorno A, Abed Y, Boivin G (May 2013). "Influenza virus resistance to neuraminidase inhibitors". Antiviral Research. 98 (2): 174–185. doi:10.1016/j.antiviral.2013.03.014. PMID   23523943.
4. "Aviragen Therapeutics - Home". Archived from the original on 2016-04-17. Retrieved 2013-04-12.
5. "Biota Pharmaceuticals - Home". Archived from the original on 2016-03-05. Retrieved 2013-04-12.
6. Ishjida T (2020). "Treatment Guidelines for Influenza Virus Infection: What Does the Recent Guideline State?". In Fujita J (ed.). Influenza: Advances in Diagnosis and Management. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Singapore: Springer. pp. 129–136 (132). doi:10.1007/978-981-15-9109-9_13. ISBN   978-981-15-9109-9. S2CID   228892521.